Obstructed shunt vessels were studied immunohistochemically to clarify the mechanism of shunt obstruction in hemodialysis patients. The subjects were 12 hemodialysis patients with shunt obstruction, and 8 patients newly started on hemodialysis were used as the controls. Cryosections of shunt tissue were prepared and stained for thrombomodulin as well as transforming growth factor-β1 using the enzyme antibody method. In the obstructed shunt group, the intima was significantly thicker than in the control group. In addition, staining of the intima for thrombomodulin was decreased in the obstructed shunt group when compared with the controls. Staining for transforming growth factor-β1 was related to intimal thickening and cell proliferation. These results indicate that release of thrombomodulin occurs with vascular endothelial cell damage and that transforming growth factor-β1 may be involved in intimal hypertrophic change and shunt obstruction.

Border WA, Ruoslahti E: Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 1992;90:1–7.
Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286–1292.
Perkett EA, Pelton RW, Meyrick B, Gold LI, Miller DA: Expression of transforming growth factor-β mRNAs and proteins in pulmonary vascular remodeling in the sheep air embolization model of pulmonary hypertension. Am J Respir Cell Mol Biol 1994;11:16–24.
Taniguchi Y, Yorioka N, Oda H, Masaki T, Usui K, Harada S, Yamakido M: Plasma thrombomodulin: Usefulness as a blood access failure marker in hemodialysis patients. Nephron 1996;73:91–93.
Nakayama M, Yamada K, Yamamoto Y, Yokoyama K, Nakano H, Kubo H, Shigematsu T, Kawaguchi Y, Sakai O: Vascular endothelial dysfunction in patients on regular dialysis treatment. Clin Nephrol 1994;42:117–120.
Ishii H, Majerus PW: Thrombomodulin is present in human plasma and urine. J Clin Invest 1985;76:2178–2181.
Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79:124–130.
Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A: Circulating thrombomodulin as a novel endothelial cell marker: Comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992;41:32–39.
Takano S, Kimura S, Ohdama S, Aoki N: Plasma thrombomodulin in health and diseases. Blood 1990;76:2024–2029.
Kreisberg JI, Garoni JA, Radnik R, Ayo SH: High glucose and TGF β1 stimulate fibronectin gene expression through a cAMP response element. Kidney Int 1994;46:1019–1024.
Pimentel JL, Sundell CL, Wang S, Kopp JB, Montero A, Martinez-Maldonado M: Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney Int 1995;48:1233–1246.
Truong LD, Pindur J, Foster S, Majesky M, Suki WN: Tenascin expression in nephrogenesis and in normal or pathologic glomerulus: Morphologic features and functional implications. Nephron 1996;72:499–506.
Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, Oohashi H, Kasayuki N, Ueda M, Morisaki N: In vivo effect of TGF-β1: Enhanced intimal thickening by administration of TGF-β1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol 1995;15:1951–1957.
Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG: Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-β1. Arterioscler Thromb Vasc Biol 1995;15:1255–1261.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.